Fulton Bank’s BioMarin Pharmaceuticals BMRN Stock Holding History

Fulton Bank’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-2,333	Closed	-$206K	–	511
2021 Q4	$206K	Buy	+2,333	New	+$193K	0.01%	515
2021 Q3	–	Sell	-4,170	Closed	-$348K	–	525
2021 Q2	$348K	Buy	4,170 +331	+9%	+$26.2K	0.02%	367
2021 Q1	$290K	Buy	3,839 +408	+12%	+$33.3K	0.01%	390
2020 Q4	$301K	Buy	3,431 +263	+8%	+$20.9K	0.02%	350
2020 Q3	$241K	Buy	3,168 +521	+20%	+$52.7K	0.01%	375
2020 Q2	$326K	Buy	2,647 +218	+9%	+$21.7K	0.02%	301
2020 Q1	$205K	Buy	+2,429	New	+$209K	0.02%	347

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Fulton Bank's BMRN Position: Q1 2022 in Review

Fulton Bank sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2022, closing a stake of 2,333 shares — an estimated $206K sold.

Fulton Bank first reported a position in BMRN in Q1 2020 and held it in 7 quarters. The position peaked at $348K in Q2 2021. 560 funds tracked by Wall St. Rank hold BMRN as of Q1 2022.

Fulton Bank reported no remaining BioMarin Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Fulton Bank sold 2,333 BioMarin Pharmaceuticals shares in Q1 2022, an estimated $206K.
Fulton Bank first reported a position in BioMarin Pharmaceuticals in Q1 2020 and held it in 7 quarters.
Fulton Bank's BioMarin Pharmaceuticals position peaked at $348K in Q2 2021.
560 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2022.

Based on Fulton Bank's 13F filing for Q1 2022, filed 5 Apr 2022.